{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:14:32Z","timestamp":1792005272975,"version":"4.4.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium falciparum<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium vivax<\/jats:named-content>\n            in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces. The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation. Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg piperaquine within 30 min to 3 h of a meal once per month for a planned 4-month period with periodic electrocardiographic and pharmacokinetic assessment. The study was halted after only 6 weeks (69 of 231 projected volunteers enrolled) when four volunteers met a prespecified cardiac safety endpoint of QTcF (Fridericia's formula for correct QT interval) prolongation of &gt;500 ms. The pharmacodynamic effect on the surface electrocardiogram (ECG) peaked approximately 4 h after piperaquine dosing and lasted 4 to 8 h. Unblinded review by the data safety monitoring board revealed mean QTcF prolongation of 46 ms over placebo at the maximum concentration of drug in serum (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) on day 2. Given that dihydroartemisinin-piperaquine is one of the few remaining effective antimalarial agents in Cambodia, compressed 2-day treatment courses of dihydroartemisinin-piperaquine are best avoided until the clinical significance of these findings are more thoroughly evaluated. Because ECG monitoring is often unavailable in areas where malaria is endemic, repolarization risk could be mitigated by using conventional 3-day regimens, fasting, and avoidance of repeated dosing or coadministration with other QT-prolonging medications. (This study has been registered at\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n            under registration no. NCT01624337.)\n          <\/jats:p>","DOI":"10.1128\/aac.02667-14","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T03:35:46Z","timestamp":1407209746000},"page":"6056-6067","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Two-Day Regimen of Dihydroartemisinin-Piperaquine for Malaria Prevention Halted for Concern over Prolonged Corrected QT Interval"],"prefix":"10.1128","volume":"58","author":[{"given":"Jessica","family":"Manning","sequence":"first","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattaraporn","family":"Vanachayangkul","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanthap","family":"Lon","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spring","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"So","sequence":"additional","affiliation":[{"name":"Royal Cambodian Armed Forces, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darapiseth","family":"Sea","sequence":"additional","affiliation":[{"name":"National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youry","family":"Se","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sok","family":"Somethy","sequence":"additional","affiliation":[{"name":"Royal Cambodian Armed Forces, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sut-Thang","family":"Phann","sequence":"additional","affiliation":[{"name":"National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soklyda","family":"Chann","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabaithip","family":"Sriwichai","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nillawan","family":"Buathong","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worachet","family":"Kuntawunginn","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashamon","family":"Mitprasat","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveewan","family":"Siripokasupkul","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paktiya","family":"Teja-Isavadharm","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Soh","sequence":"additional","affiliation":[{"name":"F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans","family":"Timmermans","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lanteri","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaranit","family":"Kaewkungwal","sequence":"additional","affiliation":[{"name":"Center for Excellence in Bioinformatics (BIOPHICS), Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montida","family":"Auayporn","sequence":"additional","affiliation":[{"name":"Center for Excellence in Bioinformatics (BIOPHICS), Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tang","sequence":"additional","affiliation":[{"name":"Fast Track Biologics, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Char Meng","family":"Chour","sequence":"additional","affiliation":[{"name":"National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satharath","family":"Prom","sequence":"additional","affiliation":[{"name":"Royal Cambodian Armed Forces, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Haigney","sequence":"additional","affiliation":[{"name":"F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Cantilena","sequence":"additional","affiliation":[{"name":"F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saunders","sequence":"additional","affiliation":[{"name":"Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.30875\/c5be4728-en"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019283"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006358"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trs019"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00686-12"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05877-11"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262125"},{"key":"e_1_3_3_9_2","volume-title":"Eurartesim. Annex I. Summary of product characteristics","author":"Sigma-Tau Industrie Farmaceutiche Riunite s.p.a.","unstructured":"Sigma-Tau Industrie Farmaceutiche Riunite s.p.a. Eurartesim. Annex I. Summary of product characteristics. Sigma-Tau Industrie Farmaceutiche Riunite s.p.a., Rome, Italy. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001199\/WC500118113.pdf."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-231"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02004.x"},{"key":"e_1_3_3_12_2","first-page":"601","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"67","author":"WHO Working Group","year":"1989","unstructured":"WHO Working Group. 1989. Glucose-6-phosphate dehydrogenase deficiency. Bull. World Health Organ. 67:601\u2013611.","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093138"},{"key":"e_1_3_3_14_2","volume-title":"Common terminology criteria for adverse events (CCTCAE), version 4.03","author":"National Cancer Institute","year":"2010","unstructured":"National Cancer Institute. 2010. Common terminology criteria for adverse events (CCTCAE), version 4.03. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90036-C"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.003723"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.447"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01962.x"},{"key":"e_1_3_3_19_2","volume-title":"EMA\/739355\/2011","author":"European Medicines Agency","year":"2011","unstructured":"European Medicines Agency. 2011. Eurartesim assessment report. EMA\/739355\/2011. Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001199\/WC500118116.pdf."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70187-1"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011880"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007871"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.11.003"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801073180101"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2005.11.026"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05688-11"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2008.11.024"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2005.01.020"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2008.05.013"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00279-11"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2407-2411.2005"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.79.620"},{"key":"e_1_3_3_33_2","first-page":"575","article-title":"The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers","volume":"35","author":"Na-Bangchang K","year":"2004","unstructured":"Na-BangchangKKrudsoodSSilachamroonUMoluntoPTasanorOChalermrutKTangpukdeeNMatangkasombutOKanoSLooareesuwanS. 2004. The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J. Trop. Med. Public Health 35:575\u2013582.","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.11-0069"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1999.60.547"},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.2000.62.402","article-title":"A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India","volume":"62","author":"Kshirsagar NA","year":"2000","unstructured":"KshirsagarNAGogtayNJMoorthyNSGargMRDalviSSChogleARSorabjeeJSMaratheSNTilveGHBhattADSaneSPMullRGathmannI. 2000. A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am. J. Trop. Med. Hyg. 62:402\u2013408.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1248\/yakushi.127.1709","article-title":"Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers","volume":"127","author":"Liu C","year":"2007","unstructured":"LiuCZhangRHongXHuangTMiSWangN. 2007. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zacchi 127:1709\u20131714.","journal-title":"Yakugaku Zacchi"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02667-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02667-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:48:12Z","timestamp":1645483692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02667-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1128\/AAC.02667-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02667-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"2014-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}